IOL Chemicals and Pharmaceuticals posts Q4 FY25 PAT at Rs. 31.42 Cr

IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025

Jubilant Pharmova posts Q4 FY25 consolidated PAT at Rs. 153.6 Cr

Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025

Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr

The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025

JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25

Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25

Remedium Lifecare secures Rs. 182.7 crore export deal

The CDMO upgrade represents a transformational step for Remedium Lifecare

Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr

GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr

The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.

Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr

The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%